The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
	Trending
	
				- 7 HLTH Announcements You Don’t Want to Miss (MedCity News)
- Practical Tips for Contracting, Part 2 (GI & Endoscopy News)
- GRAIL PATHFINDER 2 Results Show Galleri® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings (GRAIL)
- Eliminating Cost Sharing Boosted Follow-Up Colonoscopy Rates (AJMC)
- St. Charles Health System Taps WovenX to Transform GI Access and Optimize Capacity (PR Newswire)
- United Digestive adds 5 gastroenterologists in 3 months (Becker’s GI & Endoscopy)
- Negotiated Prices for Large Insurers and Regional Differences in Employed Cardiology and GI Groups Revealed (Medscape)
- Health care in the USA: money has become the mission (The Lancet)
 
		
